Full-Time

Mechanical Engineer Manager

Utilities Operations Lead

Posted on 8/17/2026

Deadline 9/5/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$99.2k - $165.4k/yr

+ 12.5% bonus target + Share-based long-term incentive program

No H1B Sponsorship

Groton, CT, USA

In Person

Onsite work is required, with occasional after-hours, weekend, emergency, and planned-shutdown response.

Bachelor's, Master's, MBA

Category
Mechanical Engineering (1)
Required Skills
Microsoft Office
HVAC
GMP
AutoCAD
Word/Pages/Docs
Risk Management
3D Modeling
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • A bachelor's degree in mechanical engineering or a related discipline is required.
  • At least 5 years of experience in utilities or central plant operations serving critical business environments is required.
  • At least 5 years of experience in engineering and maintenance of mechanical systems and infrastructure is required.
  • At least 5 years of experience in technical leadership or team support roles is required.
  • Strong knowledge of steam and thermal systems, cogeneration or turbine-based power systems, and utility distribution and mechanical systems is required.
  • Expertise in combustion turbine and cogeneration operations, steam plant generation and distribution, nitrogen generation and distribution, instrument-quality compressed air, utility and process water, integrated utilities infrastructure, and HVAC and building management systems is required.
  • Comprehensive knowledge of maintenance practices and processes is required.
  • Understanding of service level agreements and key performance indicators, including the ability to establish and collect meaningful metrics with business-line customers and colleagues, is required.
  • Proficiency with computerized maintenance management system software is required.
  • Proficiency with Microsoft Office, including PowerPoint, Excel, and Word, is required.
  • The role requires the ability to manage competing priorities in critical operations environments and exercise leadership and diplomacy in a team-oriented environment.
  • Strong verbal and written communication, interpersonal, negotiation, multitasking, and customer-service abilities are required.
  • Candidates must be authorized to work in the United States by any employer and must have permanent United States work authorization.
  • The role requires the ability to perform the specified physical activities, work in laboratories, vivaria, utility plants, and other industrial areas, and follow applicable gowning and personal protective equipment procedures.
  • The role requires day-shift availability with occasional after-hours or weekend response and emergency or off-shift support.
Responsibilities
  • Provide technical leadership and operational engineering oversight for continuous delivery of critical site utility systems and services.
  • Ensure safe, compliant, reliable, efficient, and dependable operation of central utility infrastructure and mechanical utility systems.
  • Serve as subject matter expert or site engineering lead for combustion turbine and cogeneration systems, steam, chilled water, nitrogen, instrument-quality compressed air, water, HVAC, air-handling units, exhaust, and heat exchangers.
  • Partner with Utilities Operations teams to support continuous plant reliability and performance.
  • Drive root-cause analysis, reliability improvements, and system optimization.
  • Establish and improve preventive and predictive maintenance strategies.
  • Support incident response and system recovery for critical utilities.
  • Lead and support lifecycle management of utility mechanical assets, including design, specification, commissioning, qualification, maintenance strategies, replacement, and obsolescence planning.
  • Identify and prioritize capital investments and system upgrades for mechanical infrastructure.
  • Provide engineering leadership and support for utilities-related capital projects.
  • Develop scopes, technical requirements, and commissioning plans.
  • Oversee assigned expense projects from concept through commissioning and turnover.
  • Ensure alignment with site energy strategy, sustainability, and capacity planning.
  • Ensure systems comply with applicable cGMP and GxP requirements, environmental health and safety and regulatory standards, and business resiliency requirements.
  • Support audits, inspections, and regulatory interactions.
  • Lead risk identification and mitigation for critical mechanical utilities infrastructure.
  • Oversee external service providers and utilities contractors.
  • Establish and manage key performance indicators and service level agreements for utilities operations support.
  • Ensure contract compliance and continuous improvement in service delivery.
  • Partner with Site Operations and Maintenance, EHS and Quality, and Global Engineering and Energy Management.
  • Support site-wide infrastructure reliability and operational continuity.
  • Manage outcomes of supplier-partner work for plant and building maintenance and operations and provide oversight and direction for project resources.
  • Provide indirect budgetary oversight for site utility operations and expense projects.
Desired Qualifications
  • An advanced degree, specifically a Master of Science or Master of Business Administration, is preferred.
  • Experience with reliability engineering and asset management programs is preferred.
  • Experience with distributed control systems or plant automation is preferred.
  • Experience with energy management and sustainability initiatives is preferred.
  • Experience with computer-aided facility management systems is preferred.
  • Experience with AutoCAD or other software for two-dimensional and three-dimensional modeling and documentation reviews and updates is preferred.
  • Experience leading or supporting capital projects is preferred.
  • Professional Engineer certification or equivalent is preferred.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Pfizer raised 2026 revenue guidance to $60.5-$62.5 billion on August 4, 2026.
  • Non-COVID revenue grew 5% operationally in Q2 2026, showing durable post-pandemic execution.
  • Padcev gained a new bladder-cancer approval in July 2026, expanding oncology share and pricing power.

What critics are saying

  • Eliquis faces U.S. loss of exclusivity around 2027, threatening Pfizer's biggest cash engine.
  • Pfizer cut Oxbryta after July 2026 FDA talks, proving clinical failures still destroy value.
  • Patented COVID revenue keeps collapsing; Paxlovid fell 95% in Q2 2026, removing pandemic support.

What makes Pfizer unique

  • Pfizer's global scale and regulatory reach still converts R&D into worldwide launches quickly.
  • Padcev, Vyndaqel, and Lorbrena diversified growth beyond Comirnaty and Paxlovid in Q2 2026.
  • PREVNAR 20 won Québec funding in July 2026, reinforcing Pfizer's vaccine distribution moat.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-4%
Yahoo Finance
Aug 24th, 2026
Pfizer and J&J navigate patent cliffs with newer drugs offsetting blockbuster losses

Pfizer and Johnson & Johnson are navigating patent cliffs as key drugs lose exclusivity, with their latest results showing differing stages of transition. Pfizer's revenue excluding COVID products grew 5% operationally in Q2 2026, with newer medicines like Padcev and Vyndaqel contributing. The company expects $9.7 billion in cost savings through 2029 to support margins during the transition. Johnson & Johnson's Innovative Medicine sales rose 7.8%, despite Stelara revenue declining 55%. Tremfya sales surged 72.5% to $2 billion, helping offset losses alongside growth from oncology and neuroscience products. Johnson & Johnson raised 2026 guidance, with reported sales expected to reach $101.1 billion and adjusted EPS of $11.68. Its MedTech division provides additional diversification that pure pharmaceutical company Pfizer lacks, suggesting Johnson & Johnson's transition is more advanced.

Yahoo Finance
Aug 19th, 2026
Intel CEO invests $10M in shares as chipmaker posts 25% revenue growth driven by AI demand

Intel CEO Lip-Bu Tan purchased nearly $10 million worth of shares as part of the chipmaker's recent stock offering, signalling confidence in the company's turnaround. Intel recently reported revenues of $16.1 billion, growing 25% year-over-year, with its Data Centre and AI business unit seeing revenue surge nearly 60% to $6.3 billion. CoStar Group founder and CEO Andrew Florance purchased 83,300 shares totalling roughly $2.5 million. Pfizer CEO Albert Bourla similarly invested, purchasing 38,000 shares for just over $1 million. These insider purchases reflect executives' confidence in their companies' longer-term outlook, with investors often viewing such moves as a positive signal.

Yahoo Finance
Aug 18th, 2026
Two profitable stocks with solid fundamentals and one to ignore

Two companies leverage profitability to outpace competitors, whilst another faces headwinds, according to StockStory's analysis. Primoris, which builds and maintains infrastructure in utility, energy, and civil construction sectors, struggles with a low gross margin of 10.3% reflecting high production costs. The company has seen falling earnings per share over two years and weak free cash flow margin of 2.2% over five years. BrightSpring Health Services, offering home health care and pharmacy services, has posted 23.9% annual revenue growth over two years. Its revenue base of $14.37 billion provides economies of scale. Pfizer's massive $63.7 billion revenue base gives it significant negotiating power. The pharmaceutical giant's adjusted operating margin expanded by 18.5 percentage points over two years, whilst delivering a 17.5% return on capital.

Yahoo Finance
Aug 11th, 2026
Pfizer raises 2026 guidance to $62.5B, but boost relies on Eliquis facing patent expiry

Pfizer reported second-quarter revenue of $15 billion, up 3% year over year, and raised its 2026 revenue guidance to between $60.5 billion and $62.5 billion. However, investors showed limited enthusiasm. The pharmaceutical giant's anticoagulant Eliquis, shared with Bristol Myers Squibb, generated $2.4 billion in quarterly revenue, up 21% year over year. The drug is now Pfizer's best-selling product. The concern is that Eliquis will lose patent exclusivity by the end of the decade. Pfizer's increased reliance on a drug facing imminent generic competition may signal it has yet to identify a suitable replacement. The company is expanding its pipeline, particularly in the GLP-1 market, where its candidate berobenatide is undergoing phase 3 trials after posting strong phase 2 results.

Yahoo Finance
Aug 11th, 2026
Pfizer raises guidance to $62.5B as BioNTech cuts forecast amid $928M loss

Pfizer and BioNTech reported contrasting second-quarter 2026 results as their post-pandemic strategies diverge. While the European Commission authorised their updated COVID-19 vaccine on 29 July, the former partners now face different financial realities. Pfizer posted revenues of $15 billion, up 1% operationally year-over-year. Excluding COVID products, revenue grew 5%, driven by strong performance from Eliquis, Padcev, and other non-COVID products. The company raised full-year revenue guidance by $500 million to $60.5–$62.5 billion and announced productivity initiatives expected to deliver $2.5 billion in additional savings between 2027 and 2029. BioNTech revenues fell 59.5% to €105.6 million as COVID vaccine demand declined. The company reported a net loss of €820.8 million and reduced full-year revenue guidance to €1.6–€1.9 billion. BioNTech maintains €16.6 billion in cash reserves.